WuXi STA breaks ground for second manufacturing facility in US

This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region

ResMed Q4 revenue up 4%; operating profit up 6%

The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.

Arbitrator rules in favor of Daiichi Sankyo in dispute with Seagen

All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied

Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease

Regen BioPharma develops novel dedifferentiation approach for increasing efficacy of CAR-T Cells to treat solid tumors

Company creates Younger T Cells for fighting cancer using its NR2F6 technology

Tetra Bio-Pharma secures $6,000,000 financing from Alpha Blue Ocean

IOL Chemicals and Pharmaceuticals reports Q1 FY23 revenue of Rs. 570.2 Cr

The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal

Kaléo announces appointments and new government business unit

Vijaya Diagnostic Centre Q1 FY23 revenue down 14.9%

EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%

Natco Pharma appoints Dr. Pavan Ganapati Bhat as Executive Director

He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years